Posted by Michael Wonder on 13 Apr 2021
Qilian International announces inclusion of 16 products into China's National Reimbursement Drugs List
13 April 2021 - Qilian International today announced that 16 of its products have been included in the latest version of the National Reimbursement Drugs List in China, such as aspirin enteric-coated tablets for coronary heart disease treatment, and nitrofurantoin enteric-coated tablets for the treatment of urinary tract infections.
In addition, 10 out of these 16 products have been included in the latest version of the National Essential Medicines List in China.
